Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta

International Journal of Neuroscience

Volumn 120, Issue 10, 2010, Pages 631-640

  Melanson, Maria ^a,b   Grossberndt, Amy ^b   Klowak, Meghann ^b   Leong, Christine ^b   Frost, Emma E ^b   Prout, Michael ^b   Le Dorze, Josee Anne ^b   Gramlich, Colin ^b   Doupe, Malcom ^c   Wong, Lisa ^a   Esfahani, Farid ^a   Gomori, Andrew ^a   Namaka, Michael ^a,b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cognition; expanded disability status scale; fatigue; interferon beta; multiple sclerosis; neuropsychological test

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MODIFIED FATIGUE IMPACT SCALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PHASE 4 CLINICAL TRIAL; RATING SCALE; RELAPSE;

ADOLESCENT; ADULT; AGED; COGNITION DISORDERS; DISEASE PROGRESSION; FATIGUE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77958134750     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.511732     Document Type: Article

References (58)

1. Amato, M. P., Ponziani, G., Rossi, F., Liedl, C. L., Stefanile, C., & Rossi, L. (2001). Quality of life in multiple sclerosis: The impact of depression, fatigue and disability. Multiple Sclerosis, 7, 340-344.
2. Amato, M. P., Zipoli, V., & Portaccio, E. (2006). Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. Journal of Neurological Sciences, 245, 41-46.
3. Bagert, B., Camplair, P., & Bourdette, D. (2002). Cognitive dysfunction in multiple sclerosis: Natural history, pathophysiology, and management. CNS Drugs, 16, 445-455.
4. Barak, Y., & Achiron, A. (2002). Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. European Neurology, 47, 11-14.
5. Benito-Leon, J., Morales, J. M., & Rivera-Navarro, J. (2002). Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. European Journal of Neurology, 9, 497-502.
6. Bever, C. T. Jr., Grattan, L., Panitch, H. S., & Johnson, K. P. (1995). The brief repeatable battery of neuropsychological tests for multiple sclerosis: A preliminary serial study. Multiple Sclerosis, 1, 165-169.
7. Boringa, J. B., Lazeron, R. H., Reuling, I. E., Adèr, H. J., Pfennings, L., Lindeboom, J., et al. (2001). The brief repeatable battery of neuropsychological tests: Normative values allow application in multiple sclerosis clinical practice. Multiple Sclerosis, 7, 263-267.
8. Borkan, J. M. (2004). Mixed methods studies: A foundation for primary care research. Annals of Family Medicine, 2(1), 4-6.
9. Cabrera-Gómez, J. A., Echazábal-Santana, N., Porrero-Martín, P., Valenzuela-Silva, C., Rodríguez, C. A., Fuentes-Suárez, I., et al. (2003). Interferon-alpha 2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis. Revista de Neurologia, 37, 214-220.
10. Cohen, J. (1998). Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum.
11. Crayton, H., Heyman, R. A., & Rossman, H. S. (2004). A multimodal approach to managing the symptoms of multiple sclerosis. Neurology, 63,S12-S18.
12. DeSousa, E. A., Albert, R. H., & Kalman, B. (2002). Cognitive impairments in multiple sclerosis: A review. American Journal of Alzheimer's Disease and Other Dementias, 17, 23-29.
13. Dyer, C. A. (2002). The structure and function of myelin: From inert membrane to perfusion pump. Neurochemical Research, 27(11), 1279-1292.
14. Flachenecker, P., Bihler, I., Weber, F., Gottschalk, M., Toyka, K. V., & Rieckmann, P. (2004). Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Multiple Sclerosis, 10, 165-169.
15. Filippi, M., Rocca, M. A., Columbo, B., Falini, A., Codella, M., Scotti, G., & Comi, G. (2002). Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage, 15, 559-567.
16. Fischer, J. S., Priore, R. L., Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., et al. (2000). Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple sclerosis collaborative research group. Annals of Neurology, 48, 885-892.
17. Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9-14.
18. Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994). Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clinical Infectious Diseases, 18(Suppl 1), S79-S83.
19. Flechter, S., Vardi, J., Finkelstein, Y., & Pollak, L. (2007). Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: An open-label prospective 1-year study. Israel Medical Association Journal, 9, 457-459.
20. Flensner, G., Ek, A. C., & Soderhamn, O. (2003). Lived experience of MS-related fatigue\-a phenomenological interview study. International Journal of Nursing Studies, 40, 707-717.
21. Forbes, A., While, A., Mathes, L., & Griffths, P. (2006). Health problems and health-related quality of life in people with multiple sclerosis. Clinical Rehabilitation, 20, 67-78.
22. Fritschi, C., & Quinn, L. (2010). Fatigue in patients with diabetes: A review. Journal of Psychosomatic Research, 69(1), 33-41.
23. Goebel, M. U., Baase, J., Pithan, V., Exton, M., Saller, B., Schedlowski, M., & Limmroth, V. (2002). Acute interferon [beta]-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology, 27, 881-892.
24. Halper, J., Kennedy, P., Miller, C. M., Morgante, L., Namey, M., & Ross, A. P. (2003). Rethinking cognitive function in multiple sclerosis: A nursing perspective. Journal of Neuroscience Nursing, 35, 70-81.
25. Himmerich, H., Binder, E. B., Künzel, H. E., Schuld, A., Lucae, S., Uhr, M., et al. (2006). Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biological Psychiatry, 60(8), 882-888.
26. Homewood, J., Watson, M., Richards, S. M., Halsey, J., Shepherd, P. C., & Adult Leukaemia Working Party. (2003). Treatment of CML using IFN-alpha: Impact on quality of life. Hematology Journal, 4(4), 253-262.
27. IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 655-661.
28. Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1996). Intramuscular in-terferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology, 39, 285-294.
29. Jensen, M. A., Yanowitch, R. N., Reder, A. T., White, D. M., & Arna-son, B. G. (2009) Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Multiple Sclerosis, 1, 30-38.
30. Jiang, H., Milo, R., Swoveland, P., Johnson, K. P., Panitch, H., & Dhib-Jalbut, S. (1995). Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. Journal of Neuroimmunology, 1, 17-25.
31. Kos, D., Kerckhofs, E., Nagels, G., D'hooghe, M. B., & Ilsbroukx, S. (2008). Origin of fatigue in multiple sclerosis: Review of the literature. Neurorehabilitation and Neural Repair, 22(1), 91-100.
32. Krupp, L. B. (2003a). Fatig ue. Philadelphia, PA: Elsevier Science.
33. Krupp, L. B. (2003b). Fatigue in multiple sclerosis: Defnition, patho-physiology, and treatment. CNS Drugs, 17, 225-234.
34. Krupp, L. B., & Elkins, L. E. (2000). Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology, 55, 934-939.
35. Krupp, L. B., & Rizvi, S. A. (2002). Symptomatic therapy for under-recognized manifestations of multiple sclerosis. Neurology, 58, S32-S39.
36. Leon, C., Violante, A., Arriada, N., Santana, H. R., & Corona, T. (2000). Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population. Revista de Neurologia, 31, 1019-1022.
37. Lily, O., McFadden, E., Hensor, E., Johnson, M., & Ford, H. (2006). Disease-specifc quality of life in multiple sclerosis: The effect of disease modifying treatment. Multiple Sclerosis, 12, 808-813.
38. Lim, S. Y., & Constantinescu, S. C. (2010). Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice, 64(5), 637-650.
39. Metz, L. M., Patten, S. B., Archibald, C. J., Bakker, J. I., Harris, C. J., Patry, D. G., et al. (2004). The effect of immunomodula-tory treatment on multiple sclerosis fatigue. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1045-1047.
40. Mikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., et al. (2008). Comparison of subcutaneous in-terferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing ms disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurology, 7(10), 903-914.
41. Mills, R. J., Young, C. A., Pallant, J. F., & Tennant, A. (2010). Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). Health Qual Life Outcomes, 8(22), 22.
42. Minton, O., Stone, P., Richardson, A., Sharpe, M., & Hotopf, M. (2008). Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews, 7(7), CD006704.
43. Mitchell, A. J., Benito-Leon, J., Gonzalez, J. M., & Rivera-Navarro, J. (2005). Quality of life and its assessment in multiple sclerosis: Integrating physical and psychological components of well being. Lancet Neurology, 4, 556-566.
44. Moore, F., Lee, L., Myles, M-L., Feinstein, A., Vickrey, B., Verjee, R., et al. (2008). CoMPaRe-COmparing MusiQoL and MSQoL-54 in multiple sclerosis PAtients on long-term REbif therapy. Multiple Sclerosis, 14(Suppl 1), S167.
45. Neilley, L. K., Goodin, D. S., Goodkin, D. E., & Hauser, S. L. (1996). Side effect profle of interferon beta-1b in MS: Results of an open label trial. Neurology, 46, 552-554.
46. Panitch, H., Goodin, D., Francis, G., Chang, P., Coyle, P., O'Connor, P., et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology, 59, 1496-1506.
47. Panitch, H., Goodin, D., Francis, G., Chang, P., Coyle, P., O'Connor, P., et al. (2005). Benefts of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. Journal of Neurological Sciences, 239, 67-74.
48. Patti, F., Amato, M. P., Bastianello, S., Caniatti, L., Di Monte, E., Lijoi, F., et al. (2009). Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing-remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2, 67-77.
49. Patti, F., Amato, M. P., Tola, M., Trojano, M., Ferrazza, P., Picconi, O., et al. (2008). Effects of subcutaneous interferon beta-1a on disease parameters and cognition in patients with early relapsing-remitting multiple sclerosis: Longitudinal, clinical, and cognitive results from the COGIMUS (COGnition Impairment in MUltiple Sclerosis) study. Multiple Sclerosis, 14(Suppl 1), S54.
50. Paty, D. W., & Li, D. K. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 43, 662-667.
51. Pliskin, N. H., Hamer, D. P., Goldstein, D. S., Towle, V. L., Reder, A. T., Noronha, A., et al. (1996). Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology, 47, 1463-1468.
52. Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., et al. (1983). New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Annals of Neurology, 13, 227-231.
53. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. (1998). Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.
54. Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41, 685-691.
55. Schultheis, M. T., Garay, E., & DeLuca, J. (2001). The infuence of cognitive impairment on driving performance in multiple sclerosis. Neurology, 56, 1089-1094.
56. Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., et al. (1998). Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Annals of Neurology, 43, 79-87.
57. Van Den Eede, F., Moorkens, G., Van Houdenhove, B., Cosyns, P., & Claes, S. J. (2007). Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology, 55(2), 112-120.
58. Ziemssen, T. (2009). Multiple sclerosis beyond EDSS: Depression and fatigue. Journal of Neurological Sciences, 277(Suppl 1), S37-S41.